Literature DB >> 17068196

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Gregory A Clines1, Khalid S Mohammad, Yongde Bao, Owen W Stephens, Larry J Suva, John D Shaughnessy, Jay W Fox, John M Chirgwin, Theresa A Guise.   

Abstract

Tumor-produced endothelin-1 (ET-1) stimulates osteoblasts to form new bone and is an important mediator of osteoblastic bone metastasis. The anabolic actions of ET-1 in osteoblasts were investigated by gene microarray analyses of murine neonatal calvarial organ cultures. Targets of ET-1 action were validated by real-time RT-PCR in murine primary osteoblast cultures. IL-6, IL-11, the CCN (CYR61, CTGF, NOV) family members cysteine-rich protein 61 and connective tissue growth factor, inhibin beta-A, serum/glucocorticoid regulated kinase, receptor activator of nuclear factor kappaB ligand, snail homolog 1, tissue inhibitor of metalloproteinase 3, and TG-interacting factor transcripts were increased by ET-1. ET-1 decreased the transcript for the Wnt signaling pathway inhibitor, dickkopf homolog 1 (Dkk1). Calvarial organ cultures treated with ET-1 had lower concentrations of DKK1 protein in conditioned media than control cultures. High DKK1 concentrations in bone marrow suppress bone formation in multiple myeloma. We hypothesized that the converse occurs in osteoblastic bone metastasis, where ET-1 stimulates osteoblast activity by reducing autocrine production of DKK1. Recombinant DKK1 blocked ET-1-mediated osteoblast proliferation and new bone formation in calvarial organ cultures, whereas a DKK1-neutralizing antibody increased osteoblast numbers and new bone formation. ET-1 directed nuclear translocation of beta-catenin in osteoblasts, indicating activation of the Wnt signaling pathway. The data suggest that ET-1 increases osteoblast proliferation and new bone formation by activating the Wnt signaling pathway through suppression of the Wnt pathway inhibitor DKK1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068196      PMCID: PMC2013302          DOI: 10.1210/me.2006-0346

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  62 in total

1.  LDL-receptor-related protein 6 is a receptor for Dickkopf proteins.

Authors:  B Mao; W Wu; Y Li; D Hoppe; P Stannek; A Glinka; C Niehrs
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Crème de la Kremen of Wnt signalling inhibition.

Authors:  Ute Rothbächer; Patrick Lemaire
Journal:  Nat Cell Biol       Date:  2002-07       Impact factor: 28.824

3.  Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures.

Authors:  D Gaddy-Kurten; J K Coker; E Abe; R L Jilka; S C Manolagas
Journal:  Endocrinology       Date:  2002-01       Impact factor: 4.736

4.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

5.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

6.  Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice.

Authors:  D E Clouthier; S C Williams; H Yanagisawa; M Wieduwilt; J A Richardson; M Yanagisawa
Journal:  Dev Biol       Date:  2000-01-01       Impact factor: 3.582

7.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Authors:  Randall D Little; John P Carulli; Richard G Del Mastro; Josée Dupuis; Mark Osborne; Colleen Folz; Susan P Manning; Pamela M Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael G FitzGerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina M Allen; Anthony Anisowicz; Arturo J Morales; Peter T Lomedico; Susan M Recker; Paul Van Eerdewegh; Robert R Recker; Mark L Johnson
Journal:  Am J Hum Genet       Date:  2001-12-03       Impact factor: 11.025

8.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Lynn M Boyden; Junhao Mao; Joseph Belsky; Lyle Mitzner; Anita Farhi; Mary A Mitnick; Dianqing Wu; Karl Insogna; Richard P Lifton
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

Review 9.  Role of Wnts in prostate cancer bone metastases.

Authors:  Christopher L Hall; Sona Kang; Ormond A MacDougald; Evan T Keller
Journal:  J Cell Biochem       Date:  2006-03-01       Impact factor: 4.429

10.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application.

Authors:  C Li; W Hung Wong
Journal:  Genome Biol       Date:  2001-08-03       Impact factor: 13.583

View more
  68 in total

Review 1.  The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis.

Authors:  John A Arnott; Alex G Lambi; Christina Mundy; Honey Hendesi; Robin A Pixley; Thomas A Owen; Fayez F Safadi; Steven N Popoff
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

Review 2.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

Review 3.  Wnt signaling and skeletal development.

Authors:  Fei Liu; Sean Kohlmeier; Cun-Yu Wang
Journal:  Cell Signal       Date:  2007-11-28       Impact factor: 4.315

4.  Mechanical loading regulates NFATc1 and beta-catenin signaling through a GSK3beta control node.

Authors:  Buer Sen; Maya Styner; Zhihui Xie; Natasha Case; Clinton T Rubin; Janet Rubin
Journal:  J Biol Chem       Date:  2009-10-19       Impact factor: 5.157

5.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

6.  Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.

Authors:  Jingchao Lu; Fan Liu; Demin Liu; Hong Du; Jie Hao; Xiuchun Yang; Wei Cui
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-22

7.  Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone Metastasis.

Authors:  Henry H Moon; Katrina L Clines; Mark A Cooks; Charlotte A Cialek; Marian A Esvelt; Gregory A Clines
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

8.  Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts.

Authors:  Rongrong Zhang; Babatunde O Oyajobi; Stephen E Harris; Di Chen; Christopher Tsao; Hong-Wen Deng; Ming Zhao
Journal:  Bone       Date:  2012-09-29       Impact factor: 4.398

9.  Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.

Authors:  Dali Zheng; Keith F Decker; Tianhua Zhou; Jianquan Chen; Zongtai Qi; Kathryn Jacobs; Katherine N Weilbaecher; Eva Corey; Fanxin Long; Li Jia
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

10.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.